Is Fulcrum Therapeutics, Inc. (FULC) a Buy, Sell, or Hold?
NASDAQ : FULC
Fulcrum Therapeutics, Inc.
$3.65 USD
$0.15 (4.29%)
- Volume
- 2.3M
- Average Volume
- 2.39M
- Market Capitalization
- $197.51M
- P/E Ratio
- -3.17
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $15.74
- Year Low
- $2.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $34.33
Company Overview
NASDAQ
Alexander C. Sapir
Biotechnology
Healthcare
FULC
55
US
USD
Liquidity Metrics
0.02
34.33
34.33
5.10
0.00
Sales & Valuation
-$
0.00
0.83
-3.09
-0.84
Profitability
-$1.18
-$74.88M
0.00%
0.00%
-27.80%
-21.95%
P/E Metrics
-3.17
0.00
0.00
Analyst Price Target & Rating
$4.00
$4.00
$3.00
2/5
17 Analysts
-8.75%
Poll Results
About Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notabl ... y a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
2026-07-17 17:00:00
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky
2026-06-09 09:00:00
Fulcrum Therapeutics, Inc. stock lost roughly half its value after the FDA flagged class-wide safety concerns about the entire PRC2 inhibitor drug class -- forcing immediate discontinuation of pociredicr and a full strategic review. NEW YORK, June 9, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares fell approximately 50% on June 1, 2026, after the company disclosed that the FDA had raised safety concerns about PRC2 inhibition.
2026-06-05 10:36:08
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2026-06-05 09:00:00
Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate
2026-06-04 14:53:00
NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The single-session collapse followed Fulcrum's June 1, 2026 Form 8-K, which.
What's Going On With Fulcrum Therapeutics Stock On Thursday?
2026-06-04 10:22:01
Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant challenges following its decision to discontinue pociredir, its lead experimental drug for sickle cell disease.
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
2026-06-03 12:01:11
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
2026-06-03 09:00:00
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) lost approximately 50% of its value in a single session after disclosing on June 1, 2026, that the FDA had raised class-wide safety concerns about PRC2-targeting agents, leading the Company to discontinue the program of its lead candidate pociredir. Shareholders who lost money on their FULC investment are encouraged to submit their information here.
Frequently Asked Questions
-
What is the current Fulcrum Therapeutics, Inc. (FULC) stock price?
-
Fulcrum Therapeutics, Inc.(NASDAQ:FULC) stock price is $3.65 in the last trading session. During the trading session, FULC stock reached the peak price of $15.74 while $2.83 was the lowest point it dropped to. The percentage change in FULC stock occurred in the recent session was 4.29% while the dollar amount for the price change in FULC stock was $0.15.
-
FULC's industry and sector of operation?
-
The NASDAQ listed FULC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FULC?
-
Alexander C. Sapir | Chief Executive Officer, President & Director
Gregory Tourangeau | Controller & Principal Accounting Officer
Jeffrey W. Jacobs | Chief Scientific Officer
Rudolf Jaenisch | Founder
Curtis G. Oltmans | Chief Legal Officer, Head of External Affairs & Corporate Secretary -
How many employees does FULC have?
-
Number of FULC employees currently stands at 55. FULC operates from 26 Landsdowne Street, Cambridge, MA 02139, US.
-
Link for FULC official website?
-
Official Website of FULC is: https://www.fulcrumtx.com
-
How do I contact FULC?
-
FULC could be contacted at phone #617 651 8851 and can also be accessed through its website. FULC operates from 26 Landsdowne Street, Cambridge, MA 02139, US.
-
How many shares of FULC are traded daily?
-
The average number of FULC shares traded daily for last 3 months was 2.39M.
-
What is the market cap of FULC currently?
-
The market value of FULC currently stands at $197.51M with its latest stock price at $3.65